JP2003507341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003507341A5 JP2003507341A5 JP2001516568A JP2001516568A JP2003507341A5 JP 2003507341 A5 JP2003507341 A5 JP 2003507341A5 JP 2001516568 A JP2001516568 A JP 2001516568A JP 2001516568 A JP2001516568 A JP 2001516568A JP 2003507341 A5 JP2003507341 A5 JP 2003507341A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- immune response
- iss
- polynucleotide
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 description 78
- 102000036639 antigens Human genes 0.000 description 77
- 108091007433 antigens Proteins 0.000 description 77
- 230000028993 immune response Effects 0.000 description 42
- 102000040430 polynucleotide Human genes 0.000 description 26
- 108091033319 polynucleotide Proteins 0.000 description 26
- 239000002157 polynucleotide Substances 0.000 description 26
- 239000003607 modifier Substances 0.000 description 19
- 230000004044 response Effects 0.000 description 15
- 230000002519 immonomodulatory effect Effects 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 238000009739 binding Methods 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- -1 immunomodulatory Proteins 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14976899P | 1999-08-19 | 1999-08-19 | |
| US60/149,768 | 1999-08-19 | ||
| PCT/US2000/022835 WO2001012223A2 (en) | 1999-08-19 | 2000-08-18 | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003507341A JP2003507341A (ja) | 2003-02-25 |
| JP2003507341A5 true JP2003507341A5 (enExample) | 2012-01-26 |
Family
ID=22531721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516568A Pending JP2003507341A (ja) | 1999-08-19 | 2000-08-18 | 免疫刺激配列およびそれを使用するための組成物を用いて免疫応答を調節するための方法およびそれを使用するための組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7479285B1 (enExample) |
| EP (1) | EP1204425B1 (enExample) |
| JP (1) | JP2003507341A (enExample) |
| AT (1) | ATE419869T1 (enExample) |
| AU (1) | AU774380B2 (enExample) |
| CA (1) | CA2380947C (enExample) |
| DE (1) | DE60041335D1 (enExample) |
| WO (1) | WO2001012223A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| ATE335510T1 (de) | 1998-05-22 | 2006-09-15 | Ottawa Health Research Inst | Methoden und produkte zur induzierung mukosaler immunität |
| WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US7479285B1 (en) | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| AU2001227889A1 (en) | 2000-01-14 | 2001-07-24 | The United States of America, represented by The Secretary, Department of Health & Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| AU2002231336B2 (en) | 2000-12-27 | 2007-06-28 | Surefire Medical, Inc. D/B/A Trisalus Life Sciences | Immunomodulatory polynucleotides and methods of using the same |
| NZ530635A (en) * | 2001-06-15 | 2007-03-30 | Nordic Vaccine Technology As | Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first |
| AU2002345847B2 (en) | 2001-06-21 | 2008-05-29 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP4607452B2 (ja) | 2001-08-07 | 2011-01-05 | ダイナバックス テクノロジーズ コーポレイション | 免疫調節性組成物、製剤およびその使用方法 |
| US7354909B2 (en) | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US7884083B2 (en) * | 2002-08-12 | 2011-02-08 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
| MXPA05004588A (es) | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c. |
| EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES |
| WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
| PT1575977E (pt) * | 2002-12-23 | 2009-12-15 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| ATE491463T1 (de) | 2003-02-20 | 2011-01-15 | Univ Connecticut Health Ct | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen |
| EP2007421A2 (en) | 2005-03-04 | 2008-12-31 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients. |
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
| JP2010536878A (ja) * | 2007-08-21 | 2010-12-02 | ダイナバックス テクノロジーズ コーポレイション | インフルエンザタンパク質を製造および使用する組成物および方法 |
| MX2010008148A (es) | 2008-01-25 | 2010-10-20 | Chimerix Inc | Métodos de tratamiento de infecciones virales. |
| WO2011100698A2 (en) | 2010-02-12 | 2011-08-18 | Chimerix, Inc. | Methods of treating viral infection |
| WO2011109833A2 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | Methods of treating retroviral infections and related dosage regimes |
| US9925481B2 (en) * | 2012-02-23 | 2018-03-27 | Cummins Filtration Ip Inc. | Filter cartridge endplate with integrated flow structure |
| US9649375B2 (en) | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
| US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| US4910300A (en) | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
| EP0983289A4 (en) | 1997-05-19 | 2001-04-25 | Merck & Co Inc | OLIGONUCLEOTIDE AIDS |
| DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| ATE432348T1 (de) * | 1997-06-06 | 2009-06-15 | Univ California | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
| US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| EP1872786A1 (en) | 1997-09-05 | 2008-01-02 | The Regents of the University of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
| EP1078053B1 (en) * | 1998-05-14 | 2005-09-28 | Coley Pharmaceutical GmbH | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| AU3760100A (en) | 1999-03-16 | 2000-10-04 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
| ES2250151T3 (es) | 1999-06-29 | 2006-04-16 | Glaxosmithkline Biologicals S.A. | Uso de cpg como adyuvante de vacuna contra vih. |
| US7479285B1 (en) * | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| UA77152C2 (en) | 1999-09-25 | 2006-11-15 | Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma | |
| JP2003510290A (ja) | 1999-09-27 | 2003-03-18 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激核酸誘導インターフェロンに関する方法 |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| WO2001055341A2 (en) | 2000-01-31 | 2001-08-02 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| WO2001062207A2 (en) | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| EP1267618A1 (en) | 2000-03-28 | 2003-01-02 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
-
2000
- 2000-08-18 US US09/642,492 patent/US7479285B1/en not_active Expired - Fee Related
- 2000-08-18 DE DE60041335T patent/DE60041335D1/de not_active Expired - Lifetime
- 2000-08-18 WO PCT/US2000/022835 patent/WO2001012223A2/en not_active Ceased
- 2000-08-18 EP EP00955749A patent/EP1204425B1/en not_active Revoked
- 2000-08-18 CA CA2380947A patent/CA2380947C/en not_active Expired - Fee Related
- 2000-08-18 AT AT00955749T patent/ATE419869T1/de not_active IP Right Cessation
- 2000-08-18 JP JP2001516568A patent/JP2003507341A/ja active Pending
- 2000-08-18 AU AU67899/00A patent/AU774380B2/en not_active Ceased
-
2008
- 2008-11-13 US US12/270,662 patent/US8333980B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003507341A5 (enExample) | ||
| KR100900837B1 (ko) | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 | |
| Bienzle et al. | Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease | |
| ES2328697T5 (es) | Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido | |
| JP7080513B2 (ja) | 有効成分としてリポペプチド挿入リポソームを含むワクチンアジュバントおよびその使用 | |
| Tomai et al. | TLR7/8 agonists as vaccine adjuvants | |
| Brennan et al. | Cowpea mosaic virus as a vaccine carrier of heterologous antigens | |
| JP4743928B2 (ja) | 処方物 | |
| JPH06509344A (ja) | 細胞毒性ｔ−リンパ球応答の誘導 | |
| US20020136722A1 (en) | Vaccination method | |
| JPH04210925A (ja) | 鼻腔内または吸入投与用ワクチン製剤およびその製造方法 | |
| KR101751376B1 (ko) | 점막 백신 | |
| JP2007513992A (ja) | 自己免疫疾患の治療用のｉｌ−１２又はｉｌ−２３を含むワクチン | |
| CA2372181A1 (en) | Adjuvant combination formulations | |
| JPH05504756A (ja) | 免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用 | |
| JPH0454131A (ja) | 細胞毒性ｔリンパ球の特異的誘導用合成ワクチン | |
| SK59393A3 (en) | Use of il-4 to enhance immune response to immunogegens in vaccines | |
| Ebensen et al. | Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design | |
| JP2021509918A (ja) | 免疫系の変化及びアレルギー疾患の治療又は予防のための血漿免疫グロブリンと抗原特異的免疫グロブリンとの組み合わせ | |
| CN100509056C (zh) | 包含作为佐剂的i型ifn的疫苗和涉及它们的方法 | |
| EP1029549B1 (en) | Formulation of nucleic acids and acemannan | |
| JP2015091811A (ja) | ペプチドアジュバント | |
| JP2004529861A (ja) | 抗原性凝集物を得る方法と製剤におけるその使用 | |
| US6355256B1 (en) | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof | |
| EP0351876A2 (en) | Composition for potentiating vaccination effect |